FMP

FMP

Enter

PPH - VanEck Pharmaceutica...

photo-url-https://images.financialmodelingprep.com/symbol/PPH.png

VanEck Pharmaceutical ETF

PPH

NASDAQ

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

85.31 USD

-1.17 (-1.37%)

Latest PPH News

Zacks Investment Research

Aug 14, 2024

Pharma ETFs in Focus Post Solid Q2 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Read More

ETF Trends

Aug 14, 2024

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Read More

Seeking Alpha

Jul 18, 2024

PPH: A Strong Fund To Play Big Pharma

The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat recession-proof, but high costs and regulatory risks are potential drawbacks.

Read More

Zacks Investment Research

Jul 9, 2024

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Launched on 12/20/2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Read More

Zacks Investment Research

May 9, 2024

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Read More

ETF Trends

May 7, 2024

Thematic ETF Winners of the Q1 2024 Earnings Season

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Read More

Zacks Investment Research

May 7, 2024

A Look at Pharma ETFs Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Read More

ETF Trends

Apr 30, 2024

Weight-Loss Drugs Boost Case for Pharma ETFs

Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what's recently been a sluggish healthcare investment thesis.

Read More

Seeking Alpha

Apr 23, 2024

PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns

VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson, with potential for future growth.

Read More

Zacks Investment Research

Apr 17, 2024

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep